Miller G G, Davis S F, Atkinson J B, Chomsky D B, Pedroso P, Reddy V S, Drinkwater D C, Zhao X M, Pierson R N
Department of Medicine Vanderbilt University Medical School, Nashville, TN 37232-2605, USA.
Circulation. 1999 Dec 14;100(24):2396-9. doi: 10.1161/01.cir.100.24.2396.
Vascular smooth muscle cell growth factors are postulated to contribute to cardiac allograft vasculopathy (CAV). Few data quantitatively address the timing, location, or stimuli for growth factor expression and relationship to CAV.
Acidic fibroblast growth factor (aFGF) mRNA expression was determined in serial endomyocardial biopsies during the first year after transplantation. Patients with high levels of aFGF mRNA and elevations after the early posttransplant period had significantly more severe CAV than patients with low aFGF and no late elevations.
Parenchymal aFGF expression varies between patients and in the same patient over time and correlates with development of CAV.
血管平滑肌细胞生长因子被认为与心脏移植血管病变（CAV）有关。很少有数据定量分析生长因子表达的时间、位置或刺激因素以及与CAV的关系。
在移植后的第一年，通过连续的心内膜心肌活检来测定酸性成纤维细胞生长因子（aFGF）mRNA的表达。aFGF mRNA水平高且在移植后早期过后出现升高的患者，其CAV比aFGF水平低且后期无升高的患者严重得多。
实质细胞aFGF的表达在不同患者之间以及同一患者体内随时间而变化，并与CAV的发展相关。
